Home > Publications database > Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. > print

001     176881
005     20240229133722.0
024 7 _ |a 10.1007/s00392-021-01939-3
|2 doi
024 7 _ |a pmid:34546427
|2 pmid
024 7 _ |a pmc:PMC8453472
|2 pmc
024 7 _ |a 0300-5860
|2 ISSN
024 7 _ |a 1435-1285
|2 ISSN
024 7 _ |a 1861-0684
|2 ISSN
024 7 _ |a 1861-0692
|2 ISSN
024 7 _ |a altmetric:113885271
|2 altmetric
037 _ _ |a DKFZ-2021-02123
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rieder, Marina
|b 0
245 _ _ |a Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities.
260 _ _ |a Berlin
|c 2022
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1646136132_20513
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 111, pages 322–332 (2022)
520 _ _ |a Coagulopathy and venous thromboembolism are common findings in coronavirus disease 2019 (COVID-19) and are associated with poor outcome. Timely initiation of anticoagulation after hospital admission was shown to be beneficial. In this study we aim to examine the association of pre-existing oral anticoagulation (OAC) with outcome among a cohort of SARS-CoV-2 infected patients.We analysed the data from the large multi-national Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS) from March to August 2020. Patients with SARS-CoV-2 infection were eligible for inclusion. We retrospectively analysed the association of pre-existing OAC with all-cause mortality. Secondary outcome measures included COVID-19-related mortality, recovery and composite endpoints combining death and/or thrombotic event and death and/or bleeding event. We restricted bleeding events to intracerebral bleeding in this analysis to ensure clinical relevance and to limit reporting errors. A total of 1 433 SARS-CoV-2 infected patients were analysed, while 334 patients (23.3%) had an existing premedication with OAC and 1 099 patients (79.7%) had no OAC. After risk adjustment for comorbidities, pre-existing OAC showed a protective influence on the endpoint death (OR 0.62, P = 0.013) as well as the secondary endpoints COVID-19-related death (OR 0.64, P = 0.023) and non-recovery (OR 0.66, P = 0.014). The combined endpoint death or thrombotic event tended to be less frequent in patients on OAC (OR 0.71, P = 0.056).Pre-existing OAC is protective in COVID-19, irrespective of anticoagulation regime during hospital stay and independent of the stage and course of disease.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a COVID-19
|2 Other
650 _ 7 |a Oral anticoagulation
|2 Other
650 _ 7 |a SARS-CoV-2
|2 Other
650 _ 7 |a Thrombosis
|2 Other
700 1 _ |a Gauchel, Nadine
|0 0000-0002-1276-9920
|b 1
700 1 _ |a Kaier, Klaus
|b 2
700 1 _ |a Jakob, Carolin
|b 3
700 1 _ |a Borgmann, Stefan
|b 4
700 1 _ |a Classen, Annika Y
|b 5
700 1 _ |a Schneider, Jochen
|b 6
700 1 _ |a Eberwein, Lukas
|b 7
700 1 _ |a Lablans, Martin
|0 P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439
|b 8
|u dkfz
700 1 _ |a Rüthrich, Maria
|b 9
700 1 _ |a Dolff, Sebastian
|b 10
700 1 _ |a Wille, Kai
|b 11
700 1 _ |a Haselberger, Martina
|b 12
700 1 _ |a Heuzeroth, Hanno
|b 13
700 1 _ |a Bode, Christoph
|b 14
700 1 _ |a von Zur Mühlen, Constantin
|b 15
700 1 _ |a Rieg, Siegbert
|b 16
700 1 _ |a Duerschmied, Daniel
|b 17
773 _ _ |a 10.1007/s00392-021-01939-3
|0 PERI:(DE-600)2218331-0
|p 322–332
|t Clinical research in cardiology
|v 111
|y 2022
|x 1861-0692
909 C O |p VDB
|o oai:inrepo02.dkfz.de:176881
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)e4ad7b4e684492de43cfcb12e5397439
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2021
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN RES CARDIOL : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CLIN RES CARDIOL : 2021
|d 2022-11-08
920 1 _ |0 I:(DE-He78)E260-20160331
|k E260
|l Verbundinformationssysteme
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E260-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21